Therapeutic strategy of papillary microcarcinoma of the thyroid gland: A nuclear medicine perspective

Minerva Endocrinologica

Volumn 34, Issue 1, 2009, Pages 81-87

  Riemann, B ^a   Schober, O ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Diagnosis Nuclear medicine; Radionuclide imaging Thyroid neoplasms; Thyroid neoplasms

Indexed keywords

RADIOACTIVE IODINE; ANTITHYROID AGENT; RADIOPHARMACEUTICAL AGENT; THYROTROPIN; THYROXINE;

ABLATION THERAPY; ALGORITHM; CANCER INFILTRATION; HUMAN; METASTASIS; NUCLEAR MEDICINE; PAPILLARY CARCINOMA; PREVALENCE; REVIEW; RISK FACTOR; THYROID CARCINOMA; THYROID SURGERY; BLOOD; DIAGNOSTIC IMAGING; DISEASE MANAGEMENT; METHODOLOGY; MULTIMODALITY CANCER THERAPY; NEEDLE BIOPSY; PATHOLOGY; PRACTICE GUIDELINE; SCINTISCANNING; THYROID TUMOR; THYROIDECTOMY;

ANTITHYROID AGENTS; BIOPSY, FINE-NEEDLE; CARCINOMA, PAPILLARY; COMBINED MODALITY THERAPY; DIAGNOSTIC IMAGING; DISEASE MANAGEMENT; HUMANS; IODINE RADIOISOTOPES; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; RADIOPHARMACEUTICALS; RISK FACTORS; THYROID NEOPLASMS; THYROIDECTOMY; THYROTROPIN; THYROXINE;

EID: 67650360230     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Sherman SI. Thyroid carcinoma. Lancet 2003;361:501-11.
2. Rahbar K, Hutzenlaub V, Fischer RJ, Schober O, Riemann B. Risk-profile and outcome of small papillary and follicular thyroid carcinomas. Nuklearmedizin 2008;47:188-94.
3. Lerch H, Schober O, Kuwert T, Saur HB. Survival of differentiated thyroid carcinoma studied in 500 patients. J Clin Oncol 1997;15:2067-75.
4. DeLellis RA, Lloyd RV, Heitz, PU et al. World Health Organisation Classification of Tumours. Pathology and Genetics of Tumours of Endocrine organs. Lyon: IARC Press; 2004.
5. Pacini F, Schlumberger M, Dralle H, Ilisea R, Smith Y, Viersinga V. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154:787-803.
6. Reiners C, Geling M, Luster M, Farahati J, Mäder U. Epidemiologie des Schilddrüsenkarzinoms. Onkologe 2005;11:11-9.
7. Pazaitou-Panayiotou K, Capezzone M, Pacini F. Clinical features and therapeutic implication of papillary thyroid microcarcinoma. Thyroid 2007;17:1085-92.
8. Rosai J, LiVolsi VA, Sobrinho-Simoes M, Williams ED. Renaming papillary microcarcinoma of the thyroid gland: the Porto proposal. Int J Surg Pathol 2003;11:249-51.
9. Elio R, Degli Uberti E, Braverman L, Bondanelli M. Thyroid papillary microcarcinoma. A descriptive and meta-analysis study. Eur J Endocrinol 2008 Aug 19. [Epub ahead of print].
10. Fink A, Tomlinson G, Freeman JL, Rosen IB, Asa SL. Occult micropapillary carcinoma associated with benign follicular thyroid disease and unrelated thyroid neoplasms. Mod Pathol 1996;9:816-20.
11. Harach HR, Franssila KO, Wasenius VM. Occult papillary carcinoma of the thyroid. A "normal" finding in Finland. A systematic autopsy study. Cancer 1985;56:531-8.
12. Yamamoto Y, Maeda T, Izumi K, Otsuka H. Occult papillary carcinoma of the thyroid. A study of 408 autopsy cases. Cancer 1990;65:1173-9.
13. Yang GC, LiVolsi VA, Baloch ZW. Thyroid microcarcinoma: fine-needle aspiration diagnosis and histologic follow-up. Int J Surg Pathol 2002;10:133-9.
14. Papini E, Guglielmi R, Bianchini A, Crescenzi A, Taccogna S, Nardi F et al. Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. J Clin Endocrinol Metab 2002;87:1941-6.
15. Cappelli C, Pirola I, Cumetti D, Micheletti L, Tironi A, Gandossi E et al. Is the anteroposterior and transverse diameter ratio of nonpalpable thyroid nodules a sonographic criteria for recommending fine-needle aspiration cytology? Clin Endocrinol 2005;63:689-93.
16. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:109-42.
17. Nikiforov YE. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol 2008;21:S37-43.
18. Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 2006;30:216-22.
19. Viglietto G, Chiappetta G, Martinez-Tello FJ, Fukunaga FH, Tallini G, Rigopoulou D et al. RET/PTC oncogene activation is an early event in thyroid carcinogenesis. Oncogene 1995;11:1207-10.
20. Khoo ML, Freeman JL, Witterick IJ, Irish JC, Rotstein LE, Gullane PJ et al. Underexpression of p27/Kip in thyroid papillary microcarcinomas with gross metastatic disease. Arch Otolaryngol Head Neck Surg 2002;128:253-7.
21. Londero SC, Godballe C, Krogdahl A, Bastholt L, Specht L, Sørensen CH et al. Papillary microcarcinoma of the thyroid gland: is the immunohistochemical expression of cyclin D1 or galectin-3 in primary tumour an indicator of metastatic disease? Acta Oncol 2008;47:451-7.
22. Lim DJ, Baek KH, Lee YS, Park WC, Kim MK, Kang MI et al. Clinical, histopathological, and molecular characteristics of papillary thyroid microcarcinoma. Thyroid 2007;17:883-8.
23. Baudin E, Travagli JP, Ropers J, Mancusi F, Bruno-Bossio G, Caillou B et al. Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. Cancer 1998;83:553-9.
24. Lee J, Rhee Y, Lee S, Ahn CW, Cha BS, Kim KR et al. Frequent, aggressive behaviors of thyroid microcarcinomas in korean patients. Endocr J 2006;53:627-32.
25. Rahbar K, Hutzenlaub V, Fischer RJ, Schober O, Riemann B. Risk-profile and outcome of small papillary and follicular thyroid carcinomas (≤1 cm). Nuklearmedizin 2008;47:188-93.
26. Pelizzo MR, Boschin IM, Toniato A, Pagetta C, Piotto A, Bernante P et al. Natural history, diagnosis, treatment and outcome of papillary thyroid microcarcinoma (PTMC): a mono-institutional 12-year experience. Nucl Med Commun 2004;25:547-52.
27. Pisello F, Geraci G, Sciumè C, Li Volsi F, Modica G. Total thyroidectomy of choice in papillary microcarcinoma. G Chir 2007;28:13-9.
28. Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2008;35:1941-59.
29. Ito Y, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K et al. Preoperative ultrasonographic examination for lymph node metastasis: usefulness when designing lymph node dissection for papillary microcarcinoma of the thyroid. World J Surg 2004;28:498-501.
30. Dralle H, Sekulla C. Thyroid surgery: generalist or specialist? Zentralbl Chir 2005;130:428-32.
31. Dralle H, Sekulla C, Haerting J, Timmermann W, Neumann HJ, Kruse E et al. Risk factors of paralysis and functional outcome after recurrent laryngeal nerve monitoring in thyroid surgery. Surgery 2004;136:1310-22.
32. Chow SM, Law SC, Chan JK, Au SK, Yau S, Lau WH. Papillary microcarcinoma of the thyroid-Prognostic significance of lymph node metastasis and multifocality. Cancer 2003;98:31-40.
33. Dietlein M, Dressler J, Eschner W, Grünwald F, Lassmann M, Leisner B et al. Deutsche Gesellschaft für Nuklearmedizin; Deutsche Gesellschaft für Medizinische Physik. Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 3). Nuklearmedizin 2007;46:213-9.
34. Schlumberger M, Berg G, Cohen O, Duntas L, Jamar F, Jarzab B et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 2004;150:105-12.
35. Cooper DS, Specker B, Ho M, Sperling M, Ladenson PW, Ross DS et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 1998;8:737-44.
36. McGriff NJ, Csako G, Gourgiotis L, Lori C G, Pucino F, Sarlis NJ. Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med 2002;34:554-64.
37. Riemann B, Schober O. Das Kleine Schilddrüsenkarzinom. Nuklearmedizin 2007;46:113-4.